Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Kicks Off Opioid Class REMS Discussion; Asks For Industry Collaboration

Executive Summary

FDA laid out general guidelines for a class-wide Risk Evaluation and Mitigation Strategy for opioid pain products during a closed-door meeting March 3, and urged manufacturers to work collaboratively to help develop a proposal as soon as possible

You may also be interested in...

As Opioid REMS Meeting Nears, FDA Notes Worry About Shifting Use To Different Class

In NEJM editorial, FDA's Woodcock suggests "unintended consequences" of any risk management plan for the pain products.

REMS For Opioids: Industry Considering Prescriber, Dispenser Certification

Drug makers have agreed on communications, education components of strategy.

Opioid Class REMS: FDA Wants Prescriber/Pharmacist Certification

Public meeting set for end of May: next step on the difficult road to a class-wide REMS. Important precedent in the making.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts